Encyclopedia entry
5-Amino-1MQ
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last reviewed: 2026-06-16
Independent, and paid nothing. We take no commission, no referral fee and no payment from any retailer, clinic or pharmacy on this site. Outbound links are ordinary untracked links. How we are funded.
Disambiguation: this is not a peptide
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule, an inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). It is not a peptide. It appears in this encyclopedia because UK research-chemical retailers list it next to research peptides under the same research-use-only framing, and buyers researching metabolic compounds routinely encounter it in that context.
AI-friendly summary · 5-Amino-1MQ
5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme in the NAD+ salvage and nicotinamide-metabolism pathway that is highly expressed in adipose tissue. It is studied in preclinical (animal and cell) models of metabolism and obesity. It is not a peptide. There are no published human trials and no regulatory approval anywhere as of June 2026. UK research-chemical retailers sell it under research-use-only framing.
Mechanism of action
How 5-Amino-1MQ works
5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). NNMT catalyses the methylation of nicotinamide and sits within the NAD+ salvage pathway. It is highly expressed in adipose tissue and the liver. In preclinical work, reducing NNMT activity (by genetic knockdown and, separately, by small-molecule inhibition) has been studied for its effect on adipocyte energy metabolism in diet-induced-obesity animal models. Unlike incretin drugs such as semaglutide, the studied mechanism is metabolic-enzyme inhibition at the cellular level rather than central appetite suppression. Whether any of these preclinical observations translate to humans is not established by clinical evidence.
Source: Neelakantan H et al. and the NNMT-inhibition preclinical obesity literature
What it is
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule research compound that inhibits the enzyme NNMT. Interest in NNMT as a metabolic target grew after preclinical work reported that reducing NNMT activity protected against diet-induced obesity in mice. 5-Amino-1MQ is one of the small-molecule inhibitors studied in that line of research. It is sold in the UK by research-chemical retailers, often in the same catalogues as research peptides.
- · Class: small-molecule enzyme inhibitor (not a peptide).
- · Target: nicotinamide N-methyltransferase (NNMT).
- · Pathway context: nicotinamide metabolism and the NAD+ salvage pathway, highly expressed in adipose tissue.
- · Evidence: preclinical animal and cell models only.
- · Status: no human RCTs, no marketing authorisation in any country as of June 2026.
Evidence status
The evidence for 5-Amino-1MQ is entirely preclinical. The foundational interest in NNMT as a metabolic target comes from animal work reporting that NNMT knockdown protected mice against diet-induced obesity. Subsequent studies examined small-molecule NNMT inhibitors, including 5-Amino-1MQ, in animal and cell models. No human randomised controlled trials have been published. PeptideClear summarises this literature in encyclopedia format and does not extrapolate animal findings to people.
- · NNMT knockdown protected against diet-induced obesity in mouse studies (foundational work, Nature 2014).
- · 5-Amino-1MQ studied as a small-molecule NNMT inhibitor in animal and cell models.
- · No published human RCTs as of June 2026.
- · No pharmacokinetic or safety dataset in humans is publicly available.
Animal-model findings do not establish human safety or efficacy. PeptideClear publishes no dosing or human-use instructions.
Risks and unknowns
What the literature does not yet show about 5-Amino-1MQ
Known concerns
- The evidence base is preclinical. There is no human safety dataset, no characterised human dose-response, and no regulatory review of any kind.
- Research-chemical supply is not pharmaceutical-grade. Purity, identity, and contamination cannot be verified by the buyer through any public mechanism.
- NNMT sits within central NAD+ and methyl-group metabolism. Off-target and systemic effects of inhibiting it in humans are not characterised.
- Marketing that attaches weight-loss or therapeutic claims to 5-Amino-1MQ crosses into unlicensed-medicine territory and attracts MHRA enforcement.
Open questions in the literature
- Whether any preclinical metabolic effect of NNMT inhibition occurs in humans at all is not established.
- Human pharmacokinetics, bioavailability, and elimination of 5-Amino-1MQ are not publicly characterised.
- Long-term consequences of NNMT inhibition on NAD+ and methylation balance in humans are unknown.
- Interactions with medicines, supplements (including nicotinamide or NAD+ precursors), and metabolic conditions are not studied.
Regulatory note
No UK marketing authorisation. Not a controlled drug under the Misuse of Drugs Act 1971. Not scheduled under the Psychoactive Substances Act 2016. Evidence is preclinical only. Becomes an unlicensed medicinal product the moment a retailer or commentator makes therapeutic claims about it.
Important: PeptideClear publishes encyclopedia commentary only and does not recommend human use. Speak to a UK-registered prescriber before any medical decision.
Adjacent metabolic compounds
Researchers comparing metabolic-target compounds often encounter 5-Amino-1MQ alongside these peptides, which act by entirely different mechanisms:
- · MOTS-c: a mitochondrial-derived peptide studied for AMPK activation and metabolic homeostasis in animal models.
- · Tesamorelin: a GHRH analogue studied for visceral fat reduction (US-licensed as EGRIFTA for HIV-associated lipodystrophy).
- · Retatrutide: an investigational GLP-1/GIP/glucagon triple-agonist (an incretin mechanism, distinct from NNMT inhibition).
None of these compounds, nor 5-Amino-1MQ, holds a UK marketing authorisation. All are sold outside clinical settings only under research-use-only framing.
Where to learn more
- · PubMed search: 5-Amino-1MQ for the small-molecule NNMT-inhibitor literature.
- · PubMed: NNMT inhibitor obesity for the preclinical metabolic-target context.
- · UK retailer purity comparison: research peptides UK retailers.
Frequently asked questions
Is 5-Amino-1MQ a peptide?
Is 5-Amino-1MQ legal in the UK?
What does the evidence show for 5-Amino-1MQ?
How does 5-Amino-1MQ work?
Where can I learn more about 5-Amino-1MQ?
Compare UK retailers
Side-by-side comparison across UK research-chemical and peptide retailers. Trust Index ranking. Research use only.
Compare UK retailers